Kevin Halling, MD, PhD, discussed the clinical utility of RNA-sequencing methods in patients with cancer at the 2019 Association for Molecular Pathology Annual Meeting and Expo. Halling says RNA sequencing is a very powerful diagnostic technique.
Kevin Halling, MD, PhD, a consultant in the Division of Laboratory Genetics and Genomics and Department of Laboratory Medicine and Pathology at the Mayo Clinic, discussed the clinical utility of RNA-sequencing methods in patients with cancer at the 2019 Association for Molecular Pathology (AMP) Annual Meeting and Expo. Halling says RNA sequencing is a very powerful diagnostic technique.
According to Halling, these methods can be used to detect not only gene fusions in patients with cancer, but RNA sequencing can also detect point mutations and small indels. Additionally, pathologists can use RNA sequencing techniques to measure gene expression in the patient’s tumors.
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More
Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Read More